Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

A Nomogram based on pretreatment prostate specific antigen (PSA) level, tumor grade, and clinical stage has recently been developed and distributed to physicians. It was distributed to aid physicians in making treatment recommendations by predicting the probability of the final pathologic stage of clinically localized prostate carcinoma. The Nomogram was based on data for one patient population, and the validity of its application in general urologic practices had not yet been evaluated.

[1]  P. Schellhammer,et al.  Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. , 1993, Urology.

[2]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[3]  S. Mills,et al.  Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens , 1986, Cancer.

[4]  P. Troncoso,et al.  Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. , 1995, Urology.

[5]  M. Kattan,et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.

[6]  L. Holmberg,et al.  Five year follow-up after radical prostatectomy for localized prostate cancer--a study of the impact of different tumor variables on progression. , 1994, Scandinavian journal of urology and nephrology.

[7]  P. Scardino,et al.  Staging of prostate cancer: value of ultrasonography , 1989 .

[8]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[9]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[10]  R. Oyasu,et al.  The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. , 1984, The Journal of urology.

[11]  T. Peters,et al.  Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality. , 1995, British journal of urology.

[12]  T. Wheeler.  Anatomic considerations in carcinoma of the prostate. , 1989, The Urologic clinics of North America.

[13]  W. Catalona,et al.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. , 1994, The Journal of urology.

[14]  P. Humphrey,et al.  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. , 1993, The Journal of urology.

[15]  S. Cha,et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Toublanc,et al.  Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. , 1994, Urology.

[17]  R. Cote,et al.  Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. , 1995, The Journal of urology.

[18]  N. Bolton,et al.  Nuclear androgen receptors in the epithelium and stroma of human benign prostatic hypertrophic glands , 1983, The Prostate.

[19]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[20]  A W Partin,et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.

[21]  A. Pollack,et al.  Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. , 1995, Urology.

[22]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[23]  P. Humphrey,et al.  Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues , 1995 .

[24]  A. Zietman,et al.  Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. , 1994, The Journal of urology.

[25]  I. Kaplan,et al.  Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. , 1993, The Journal of urology.

[26]  T. Stamey,et al.  Serum prostate-specific antigen and the biologic progression of prostate cancer. , 1995, Urology.

[27]  R. Gittes,et al.  Prostate-specific antigen. , 1987, The New England journal of medicine.

[28]  T. Schultheiss,et al.  Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. , 1995, The Journal of urology.

[29]  P. Walsh,et al.  Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. , 1993, The Journal of urology.

[30]  M. Hunt,et al.  Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. V. von Eschenbach,et al.  Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapy , 1993, Cancer.

[32]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[33]  F. Schröder,et al.  The TNM classification of prostate cancer , 1992, The Prostate. Supplement.

[34]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[35]  G. Zagars.  Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. , 1994, The Journal of urology.

[36]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[37]  W. Catalona.  Surgical management of prostate cancer. Contemporary results with anatomic radical prostatectomy , 1995 .

[38]  E. Messing,et al.  Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Walsh,et al.  Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. , 1993, The Journal of urology.

[40]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[41]  A. Tewari,et al.  The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. , 1995, Urology.

[42]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[43]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.